Positive results in the early stages of Roche’s weight-loss pill development had given investors hope it could quickly catch up with rivals Novo Nordisk and Eli Lilly. Read More
Positive results in the early stages of Roche’s weight-loss pill development had given investors hope it could quickly catch up with rivals Novo Nordisk and Eli Lilly. Fortune | FORTUNE